Eton Pharmaceuticals, Inc.
ETONEton Pharmaceuticals is an innovative pharmaceutical company dedicated to the development and commercialization of treatments for rare diseases.
Earnings
Next report
Nov 5, 2026 (in 2 months)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Eton Pharmaceuticals is an innovative pharmaceutical company dedicated to the development and commercialization of treatments for rare diseases. The company leverages the 505(b)(2) regulatory pathway to expedite drug development by utilizing existing clinical data for new formulations or indications. Its core value proposition centers on identifying under-appreciated assets and managing them through the regulatory process to provide accurate dosing and improved administration for orphan disease populations.
Eton occupies a niche position as a specialist in rare disease treatments, utilizing the 505(b)(2) pathway to compete against both large pharmaceutical firms and generic manufacturers.
FAQ
- What is Eton Pharmaceuticals, Inc.'s market cap?
- Eton Pharmaceuticals, Inc. (ETON) has a market capitalization of $1.8B and trades on NASDAQ.
- What is Eton Pharmaceuticals, Inc.'s revenue and profitability?
- Eton Pharmaceuticals, Inc. generated $105.6M in trailing twelve-month revenue with net income of $8.6M, representing a net margin of -9.5%. Gross margin stands at 57.9%, with free cash flow of $34.3M. These figures are based on the Q2 2026 filing.
- Who are Eton Pharmaceuticals, Inc.'s competitors?
- Eton Pharmaceuticals, Inc.'s key competitors include Xeris Biopharma Holdings, Inc. Common Stock, ANI Pharmaceuticals, Inc., Zevra Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Eton Pharmaceuticals, Inc. partner with?
- Eton Pharmaceuticals, Inc.'s notable partners include AMMTeK, Crossject.
- Where is Eton Pharmaceuticals, Inc. headquartered?
- Eton Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 30 people. It has been publicly traded since 2018.
